On March 5, 2010
Lesson from an Alzheimer-Drug Failure: Beware Russian Clinical Trial Data
Pfizer (PFE) and Medivation (MDVN)’s Phase III failure of Alzheimer’s drug Dimebon (latrepirdine) serves as a reminder to pharma execs to be wary of Russian clinical trial data.
No tags for this post.
0 Comments